Automated laboratory robotics: A leap forward for pharmaceutical analysis
The Optimal Group has unveiled SciYbotic Labs, a new range of automated laboratory solutions aimed at revolutionising analytical processes in the pharmaceutical sector. This innovation promises to enhance efficiency, consistency, and profitability in drug development and quality control.
Integrating robotics with sophisticated software
At the heart of SciYbotic Labs is a combination of autonomous mobile robots (AMRs) and the synTQ software platform. This integration creates a self-contained workflow and analysis tool capable of managing both wet and dry laboratory testing without human intervention. The system is designed to be fully compliant with regulatory standards, addressing a crucial concern in pharmaceutical research and development.
The automation of routine analytical testing allows scientists to redirect their efforts towards more complex and intellectually demanding projects. This shift not only reduces costs but also maximises the value
of highly trained personnel. Moreover, the system’s automatic data capture ensures complete data integrity, a critical factor in pharmaceutical research and regulatory compliance.
Customisable and scalable solutions
SciYbotic Labs offers flexibility in its deployment, accommodating various analytical methods. The system can be configured to include static, bench-mounted robots for sample preparation and analysis, or incorporate AMRs for sample transport between facilities.
Martin Gadsby, Chairman at Optimal Group, emphasised the unique advantage of the system: “We believe the ease with which validated analytical methods can be reused by facilities around the globe with minimal revalidation to be a unique feature of our offering.”
Standardisation across global facilities
The synTQ software, which manages workflow execution and data analysis, facilitates standardisation across a company’s global facilities. This feature allows pharmaceutical companies to implement consistent analytical methods across different laboratories worldwide, potentially reducing the need for repeated method validation.
As the pharmaceutical industry continues
to seek ways to streamline processes and improve consistency, solutions like SciYbotic Labs look set to play a crucial role in shaping the future of drug development and quality control. The potential for increased efficiency and global standardisation could have significant implications for accelerating drug discovery and ensuring consistent product quality across markets.
For more information, visit: www.sciy.com
Digital issue: Please click here for more information
